Abstract:
زیستفناوری پزشکی یا درمانی به توسعه ابزارهای تحقیقاتی، تشخیص، توسعه و تحویل داروها و واکسنها از طریق استفاده از سیستمها یا فرآیندهای سلولی و مولکولهای زیستی اختصاص دارد. یک انتخاب استراتژیک بسیار مهم شرکتها در صنعت داروهای زیستی، استراتژی تجاریسازی فناوری است. استراتژی تجاریسازی مستقل بهعنوان یکی از استراتژیهای تجاریسازی داروهای زیستی در دنیا شناخته شده است. هدف پژوهش حاضر شناسایی پیشبینهای عملکرد استراتژی تجاریسازی مستقل در صنعت زیستداروی ایران با استفاده از روش فراترکیب است. در این روش پس از فیلتر مقالات، در نهایت تعداد 42 تحقیق که بطور مستقیم به موضوع عملکرد تجاریسازی مستقل در داروهای زیستی پرداخته بودند وارد مرحله تحلیل در نرمافزار مکسکیودا شدند. پس از مرحله تلفیق تعداد 68 رمز متمایز شناسایی، و در سطوح انتزاع بالاتر رمزها در قالب 9 تم (جهتگیری استراتژیک، هوش تجاریسازی فناوری، قابلیت R&D، یکپارچگی دانش توسعه محصول، قابلیت تجاریسازی (تولید و بازاریابی)، مکانیسم حمایتی دولت و رژیمهای مالکیت، یکپارچگی رسمی و پویائی محیطی) قرار داده شدند. بهمنظور ساخت مدل مفهومی پژوهش، براساس خروجی فراترکیب، سازههای پیشبین عملکرد استراتژی تجاریسازی مستقل، نحوه ارتباط سازهها و نیز شاخصهای اندازهگیری آنها استخراج شدند. نتیجه اعتبارسنجی مدل پیشنهادی براساس نظر خبرگان صنعت زیستداروئی کشور با روش رتبه اعتبار محتوایی لاوش و تکنیک حداقل مربعات جزئی از این قرار است: پیشبینهای عملکرد استراتژی تجاریسازی مستقل با ضریب تعیین 91% عبارتند از: یکپارچگی رسمی و غیررسمی، جهتگیریهای استراتژیک، هوش تجاریسازی فناوری، قابلیتR&D، قابلیت تولید و بازاریابی.
Abstract Medical or therapeutic biology is dedicated to the development of research tools, diagnosis, development and delivery of drugs and vaccines through the use of cellular systems or processes and biological molecules. A very important strategic choice of companies in the biological drug industry is technology trading strategy. Independent commercialization strategy is recognized as one of the trade drugs in the world. The purpose of the present study is to identify predictions for the performance of independent commercialization strategy in Iran's biological industry using a comprehensive method. In this method, after the filtering of the articles, finally 42 studies that directly addressed the performance of independent commercialization in biological drugs entered the analysis phase of the Maxicioda software. After the combination of 68 distinct passwords, and at higher abstraction levels of the passwords in the form of 9 themes (strategic orientation, technology commercialization intelligence, R&D capability, product development knowledge integration, commercialization (production and marketing), The state -supporting mechanism of government and ownership regimes, formal integration and environmental dynamics were set. In order to construct the conceptual model of the research, they were extracted based on the component output, predictive structures of independent trading strategy, how the structures communication, and their measurement indicators were extracted. The validity of the proposed model based on the country's biotechnology experts with the Lavos content validity method and the minimum square minimum technique is: Independent commercial strategy performance predictions with a 91% determination coefficient include: Official integrity and integrity. Innovation, strategic orientation, technology commercialization, R&D capability, production capability and marketing. Introduction Biotechnology is an important part of the society and economy of Iran. In the world, 140 drugs are produced from biotechnology, of which 16 are the most commonly used drugs. Nowadays 9 biotechnology and vaccine drugs such as hepatitis B drugs and various types of interferons (alpha, gamma and beta) are produced inside the country, producing 250 billion tomans worth of currency savings for the country. About $ 8 billion worth of biotechnology imports into the country are expected to cost $ 150 billion annually, which is expected to increase by about 900-800 billion USD annually. Biotechnology drugs are expensive drugs and if we can plan to produce these drugs in the next five years, we have to pay a thousand billion dollars for the import of such drugs, which will disrupt the health and medicine system of the country. This implicitly implies the necessity of commercialization, the formulation of commercialization strategies, and the successful performance of commercialization strategies in the field of biotechnology (Kebriaeezadeh et al., 2010). The question that is posed is that the predictors (determinants) of the operation of the independent commercialization strategy in Iran's bio-environmental industry? Case Study In the present research, the industry of biological drugs in Iran has been studied. Materials and Method The present study is based on the results of development; on the basis of purpose, explanatory-descriptive and based on the type of data is quantitative and the research quality is a hypothesis test. The design of the research has been done according to the five-step approach presented by McKinsey et al. (1999). Accordingly, the research stages are as follows: the design of the research includes the explanation of the problem and the review of the theoretical background; the formulation of a conceptual framework and the determination of the components and relevant indicators; validation of the research including general validation, validation of the research tool and data collection; analysis and Data analysis; Reporting the results of the research including summarizing the findings of research and writing the analyzes of the researchers. Results and Discussion Considering the content validity ratios calculated, in the conceptual model, the predictors of the performance of the independent commercialization strategy, the factors; the strategic orientation, the formal and informal integration of research units with the units of production and marketing, the ability to R & D, commercialization and intelligence of technology commercialization are the determinants of the operation of an independent commercialization strategy in the country's biotechnology industry.According to the model of performance prediction of independent commercialization strategy in the country's biotechnology industry, the following hypotheses have been developed. Hypothesis 1. There is a significant relationship between BI-technology intelligence and the performance of the development of a new biological medicine. Hypothesis 2. There is a significant relationship between the integrity (formal and informal) and the performance of the development of the new biological drug. Hypothesis 3. There is a significant relationship between firm strategic orientation and technology commercialization intelligence. Hypothesis 4. There is a significant relationship between the R & D capability and the performance of the new biological drug development. Hypothesis 5. There is a significant relationship between the commercialization (production and marketing) of the firm and the performance of the development of the new biological drug. Hypothesis 6. There is a significant relationship between R & D capability and commercialization (production and marketing) capabilities of the firm. Conclusion Considering the significant relationships between the structure of the company's research and development capability, the structure of the enterprise's commercialization (production and marketing), the strategic directional structure of the firm, the formal and informal integration structure, the technology intelligence technology intelligence structure with the performance of the new product development, It can be said that in the case of: the existence of a suitable R & D workforce, proportional investment in R & D, and ..., we can expect a successful performance (the realization of new product objectives; new product life cycle management; the success of engaging in business activities; Making technology in comparison with direct rivals of the company; a significant increase in corporate revenues versus commercialization revenues Direct use; the company's more successful use of technology commercialization for strategic purposes in comparison with its competitors; providing unique features to customers; increasing the number of patents obtained from the new product development program; receiving good returns to costs; The program used for the new product development program and the competitiveness of the new product in the market) had an independent commercialization strategy.
Machine summary:
هدف پژوهش حاضر شناسايي پيش - بين هاي عملکرد استراتژي تجاريسازي مستقل در صنعت زيست داروي ايران با استفاده از روش فراترکيب است .
نتيجه اعتبارسنجي مدل پيشنهادي براساس نظر خبرگان صنعت زيست - داروئي کشور با روش رتبه اعتبار محتوايي لاوش و تکنيک حداقل مربعات جزئي از اين قرار است : پيش بين هاي عملکرد استراتژي تجاريسازي مستقل با ضريب تعيين ٩١% عبارتند از: يکپارچگي رسمي و غيررسمي، جهت گيري - هاي استراتژيک ، هوش تجاريسازي فناوري، قابليت R&D، قابليت توليد و بازاريابي.
پايگاه هاي دانشي پويا از جمله ؛ ژنوم ها، زيست شناسي مولکولي، و پروتئوميکس ١ها، نوبودن و سيال بودن دانش علمي و فني صنعت زيست فناوري، که براي توسعه محصولات جديد لازم است ، نشان مي - دهد که انتخاب استراتژي تجاريسازي مناسب يکي از تصميم هاي مهم شرکت هاي فعال در اين حوزه است (٢٧٠ :٢٠٢١ ,shakeri, Yaghoubi).
١٩٩٠,Shan ٢٠١٠ ,Welpe)، پشتيباني و حمايت از سوي بخش تحقيقات دانشگاهي (,Rasmussen (٢٠٢٠ ,Murgia &Messeni Petruzzelli ;٢٠٠٨)، زيرساختار تکنولوژي فراهم شده توسط دولت (٢٠١٠ ,Link and Scott)، فرهنگ کارآفريني (Jiang et ;٢٠٠٢ ,Conceicao et al ٢٠١٦ ,.
بعلاوه سنجش اعتبار مدل پيش بين هاي عملکرد استراتژي تجاريسازي مستقل داروهاي زيستي در ايران ، از طريق مراحل اعتبارسنجي لاوش صورت گرفته است .
(به تصویر صفحه رجوع شود) شکل شماره ٢: مدل مفهومي پيشنهادي پيش بين هاي عملکرد استراتژي تجاري سازي مستقل در صنعت داروهاي زيستي نتايج اعتبارسنجي مدل مفهومي پيشنهادي پژوهش همان گونه که مزبور افتاد براي اعتبارسنجي خروجيهاي فراترکيب از تکنيک اعتبار محتوايي لاوش استفاده شده است .